Larsen & Toubro Infotech (LTI) has entered into a partnership with eClinicalHealth Ltd to accelerate digital innovation in R&D clinical trials management process for patient-centric drug development. The partnership will help clients decentralise clinical trials setting new benchmarks of excellence in the clinical research space.

The significance of the tie-up is based on the fact that 86 per cent of clinical studies are delayed due to challenges in patient engagement – mainly involving recruitment and retaining patients, which is a time consuming and expensive process. The pandemic has further aggravated this challenge. It is in this context that eClinicalHealth, which is focused on developing innovative clinical trial solutions, launched a cloud-based patient-centric SaaS solution, Clinpal – which improves patient engagement for each clinical trial journey.  

As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters. The solution will make use of exponential technologies such as analytics and AI to enhance patient engagement and faster clinical studies.

Archana Ramanakumar, EVP & Global Delivery Head – Life Sciences, Media, Consumer & Technology, LTI commented: "At LTI, we are on a journey to drive digital transformation for various aspects of clinical trials. Our endeavour with eClinicalHealth partnership is to accelerate and streamline the enablement of decentralized trials, to reduce patient burden and drive the acceleration of clinical trials. With this partnership, we aim to accelerate the development and deployment of eClinicalHealth's ClinPal platform in clinical trials for the industry."

Karl Landert, Chairman of the Board and CEO at eClinicalHealth said: "The new normal world has put into limelight the benefits of a telemedicine ecosystem for the larger benefit of end-users. Clinical trials assume an important function in the development and improvement of treatment methods to enhance patient's wellbeing, and de-centralized trials have attained the highest order of patient preference. With our strategic partnership with LTI, we aim to further scale and simplify patient engagement."